Semaglutide

Semaglutide is a GLP-1 receptor agonist peptide widely studied in metabolic and endocrine research. It is a synthetic analog of native glucagon-like peptide-1 with strategically placed amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, dramatically extending its plasma half-life to approximately 7 days.

As an agonist at the GLP-1 receptor, semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and modulates appetite signaling centers in the hypothalamus. It is approved as a pharmaceutical in multiple countries but supplied here as research-grade material for laboratory use only.

• GLP-1 receptor pharmacology and downstream signaling
• Glucose homeostasis and insulin secretion studies
• Appetite and satiety modulation research
• Gastric emptying and gastrointestinal motility research
• Cardiovascular risk factor research in metabolic disease models
• Comparison with other GLP-1 analogs (liraglutide, dulaglutide, etc.)

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

GLP-1 agonist. May titrate every 4 weeks. Subcutaneous injection.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.